219 related articles for article (PubMed ID: 8917247)
1. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin.
Aoyama T; Sunakawa K; Iwata S; Takeuchi Y; Fujii R
J Pediatr; 1996 Nov; 129(5):761-4. PubMed ID: 8917247
[TBL] [Abstract][Full Text] [Related]
2. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis.
Langley JM; Halperin SA; Boucher FD; Smith B;
Pediatrics; 2004 Jul; 114(1):e96-101. PubMed ID: 15231980
[TBL] [Abstract][Full Text] [Related]
3. Antibiotics for whooping cough (pertussis).
Altunaiji S; Kukuruzovic R; Curtis N; Massie J
Cochrane Database Syst Rev; 2005 Jan; (1):CD004404. PubMed ID: 15674946
[TBL] [Abstract][Full Text] [Related]
4. Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015.
Jakubů V; Zavadilová J; Fabiánová K; Urbášková P
Cent Eur J Public Health; 2017 Dec; 25(4):282-286. PubMed ID: 29346850
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial.
Lebel MH; Mehra S
Pediatr Infect Dis J; 2001 Dec; 20(12):1149-54. PubMed ID: 11740322
[TBL] [Abstract][Full Text] [Related]
6. Antibiotics for whooping cough (pertussis).
Altunaiji S; Kukuruzovic R; Curtis N; Massie J
Cochrane Database Syst Rev; 2007 Jul; (3):CD004404. PubMed ID: 17636756
[TBL] [Abstract][Full Text] [Related]
7. The First Report of Macrolide-Resistant Bordetella pertussis Isolation in Japan.
Yamaguchi T; Kawasaki Y; Katsukawa C; Kawahara R; Kawatsu K
Jpn J Infect Dis; 2020 Sep; 73(5):361-362. PubMed ID: 32350216
[TBL] [Abstract][Full Text] [Related]
8. Short-term treatment of pertussis with azithromycin in infants and young children.
Baće A; Zrnić T; Begovac J; Kuzmanović N; Culig J
Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):296-8. PubMed ID: 10385021
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibility testing of Bordetella pertussis in Taiwan prompted by a case of pertussis in a paediatric patient.
Yao SM; Liaw GJ; Chen YY; Yen MH; Chen YH; Mu JJ; Chiang CS
J Med Microbiol; 2008 Dec; 57(Pt 12):1577-1580. PubMed ID: 19018032
[TBL] [Abstract][Full Text] [Related]
10. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines.
Tiwari T; Murphy TV; Moran J;
MMWR Recomm Rep; 2005 Dec; 54(RR-14):1-16. PubMed ID: 16340941
[TBL] [Abstract][Full Text] [Related]
11. Azithromycin for the treatment of pertussis.
Pichichero ME; Hoeger WJ; Casey JR
Pediatr Infect Dis J; 2003 Sep; 22(9):847-9. PubMed ID: 14515842
[No Abstract] [Full Text] [Related]
12. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
[TBL] [Abstract][Full Text] [Related]
13. Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis.
Hoppe JE; Eichhorn A
Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):653-4. PubMed ID: 2550234
[TBL] [Abstract][Full Text] [Related]
14. [Susceptibility to macrolide antibiotics of Bordetella pertussis and Bordetella parapertussis strains isolated from whooping cough patients in 1968 and in 1997-99].
Chodorowska M; Kuklińska D; Tyski S
Med Dosw Mikrobiol; 2001; 53(1):39-43. PubMed ID: 11757403
[TBL] [Abstract][Full Text] [Related]
15. Clinical manifestations of children with microbiologically confirmed pertussis infection and antimicrobial susceptibility of isolated strains in a regional hospital in Japan, 2008-2012.
Horiba K; Nishimura N; Gotoh K; Kawaguchi M; Takeuchi S; Hattori F; Isaji M; Okai Y; Hosono H; Takemoto K; Ozaki T
Jpn J Infect Dis; 2014; 67(5):345-8. PubMed ID: 25241683
[TBL] [Abstract][Full Text] [Related]
16. Minimum inhibitory concentrations of erythromycin and other antibiotics for Czech strains of Bordetella pertussis.
Jakubů V; Zavadilová J; Fabiánová K; Urbášková P
Epidemiol Mikrobiol Imunol; 2015 Mar; 64(1):12-5. PubMed ID: 25872990
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin/piperacillin-tazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates: A single-centre study in Zhejiang Province, China.
Hua CZ; Wang HJ; Zhang Z; Tao XF; Li JP; Mi YM; Tang LF; Chen ZM
J Glob Antimicrob Resist; 2019 Sep; 18():47-51. PubMed ID: 30710647
[TBL] [Abstract][Full Text] [Related]
18. Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: a randomized controlled trial.
Cascio A; Colomba C; Antinori S; Paterson DL; Titone L
Clin Infect Dis; 2002 Jan; 34(2):154-8. PubMed ID: 11740701
[TBL] [Abstract][Full Text] [Related]
19. Macrolides in the management of streptococcal pharyngitis/tonsillitis.
Tarlow MJ
Pediatr Infect Dis J; 1997 Apr; 16(4):444-8. PubMed ID: 9109157
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine).
Hoppe JE; Bryskier A
Antimicrob Agents Chemother; 1998 Apr; 42(4):965-6. PubMed ID: 9559823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
